HIV doesn’t discriminate, but societal barriers have left Black Americans disproportionately affected. HIV prevention options ...
GlobalData on MSN
HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir
Though yet to be finalised, the initial recommendation would mean the injectable PrEP would not be covered on the NHS.
PHILADELPHIA.Today on MSN
Wistar Institute wins $15M+ NIH investment to advance HIV cure research strategies
More than 40 million people worldwide live with HIV and depend on daily antiretroviral therapy to stay alive. Federal funding ...
That's a quote from former rugby star Gareth Thomas, who is HIV positive. At the International AIDS Conference in Rio this ...
The drugmaker’s NABJ panel brought together journalists, faith leaders, advocates and celebrities as part of a push to take ...
Starting antiretroviral therapy immediately after HIV diagnosis appears to keep patients engaged in care during critical ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new sequential immunization strategy shows strong promise for an HIV vaccine, a ...
Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3% in ...
For years, Pakistan has seen cases of children infected with HIV due to unsafe treatment in clinics and hospitals. A current ...
With “Undetectable = Untransmittable,” or U = U, the message is clear: People with HIV who maintain an undetectable viral ...
In the early decades of the global response to HIV/AIDS, the focus was on saving lives. And rightly so: without antiretroviral treatment (ART), people lived less than a year, on average, from the time ...
BANGKOK: HIV attacks the immune system, while AIDS is the most advanced stage of HIV infection. Thailand's response has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results